Adagio Medical Holdings, Inc. announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company?s Audit Committee and Compensation Committee. Mr. Salmon, age 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company?s cardiovascular and diabetes businesses.

Most recently, he served as Executive Vice President and President of Medtronic?s Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Ablation, Structural Heart and Aortic, Coronary and Renal Denervation, Peripheral Vascular and Cardiac Surgery businesses. As a portfolio leader he was responsible for optimizing enterprise performance through capital allocation, talent development, strategic investments, and cross-portfolio collaboration. During his career, Mr. Salmon built extensive expertise across electrophysiology therapies, including surgical and catheter-based ablation.

He also led several strategic initiatives central to Medtronic?s growth in the EP and ablation markets, including the acquisition of Affera, the asset acquisition of Acutus? transeptal crossing technology, and the successful CE-Mark and FDA approvals for the Pulse Select and Sphere 9 pulsed field ablation catheters, followed by their global commercialization. Earlier at Medtronic, Mr. Salmon served as President of Coronary & Structural Heart, where he led all aspects of the business, including Clinical, Regulatory, Research & Development, Marketing, Sales, Operations, Supply Chain, Quality, Health Economics & Reimbursement, Business Development, Finance, and Strategy.

Under his leadership, Medtronic successfully entered the highly competitive drug-eluting stent market and expanded the company?s transcatheter aortic valve replacement franchise through successive innovation cycles, broadening treatment indications and accelerating global adoption. Mr. Salmon also previously served as Executive Vice President and President of the Medtronic Diabetes Operating Unit, where he led a multi-year portfolio transformation. Earlier in his career, he held management roles at C.R. Bard, Johnson & Johnson, SurgiVision, and EuroRSCG Life.

He holds an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.